Vivos Therapeutics (VVOS) Stock Price, News & Analysis

Company Overview

Vivos Therapeutics, Inc. engages in the development and commercialization of innovative medical technology focused on non‐surgical precision oral appliance therapy for individuals suffering from sleep‐disordered breathing, including mild‐to‐moderate obstructive sleep apnea, snoring and upper airway resistance syndrome. The company’s core offering, the Vivos System, leverages a proprietary protocol and customized oral appliances designed to reshape patient’s upper airway structures over time. Through a network of Vivos‐trained dentists and orthodontists, Vivos Therapeutics delivers a non‐invasive alternative to continuous positive airway pressure (CPAP) therapy and surgical interventions.

The Vivos System consists of a series of personalized intraoral devices, software tools for treatment planning and monitoring, and educational materials for both clinicians and patients. By integrating digital imaging, three‐dimensional modeling and evidence‐based treatment protocols, the company aims to deliver predictable outcomes and improve overall patient compliance. In addition to its flagship appliances, Vivos offers ongoing support services, training programs and clinical resources aimed at optimizing treatment efficacy and expanding practitioner adoption.

Founded in 1996 and headquartered in Louisville, Colorado, Vivos Therapeutics has built a global footprint through partnerships with dental and medical practices in North America, Europe, Australia and select markets in Asia and Latin America. The company secured a listing on the NASDAQ in late 2020 to support continued research and expansion of its product portfolio. Over the years, Vivos has participated in multiple peer‐reviewed studies and industry conferences to validate its technology and grow awareness among sleep medicine professionals.

Vivos Therapeutics is led by a seasoned management team headed by Chairman and Chief Executive Officer M. Paul Jensen, alongside Founder and Chief Medical Officer Dr. Fernando A. Uribe. With backgrounds spanning medical device development, dental science and healthcare services, the company’s executives and board members are focused on driving clinical adoption, scaling distribution and advancing ongoing research initiatives aimed at enhancing patient outcomes in the sleep‐disordered breathing space.

Key Stats

• Today's Range: $5.90 to $6.73
• 50-Day Range: $2.08 to $6.95
• 52-Week Range: $1.97 to $7.95
• Volume: 490,944 shs
• Average Volume: 616,049 shs
• Market Capitalization: $35.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.82
• Consensus Rating: Moderate Buy

Vivos Therapeutics Stock Analysis - MarketRank™

Vivos Therapeutics scored higher than 26% of companies evaluated by MarketBeat, and ranked 820th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vivos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Vivos Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vivos Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vivos Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vivos Therapeutics is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vivos Therapeutics has a P/B Ratio of 4.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.56% of the float of Vivos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vivos Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vivos Therapeutics has recently decreased by 70.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vivos Therapeutics does not currently pay a dividend.

Dividend Growth

Vivos Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.56% of the float of Vivos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vivos Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vivos Therapeutics has recently decreased by 70.96%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Vivos Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Vivos Therapeutics this week, compared to 1 article on an average week.

Search Interest

7 people have searched for VVOS on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Vivos Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vivos Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.00% of the stock of Vivos Therapeutics is held by insiders.

Percentage Held by Institutions

Only 26.35% of the stock of Vivos Therapeutics is held by institutions.

VVOS Stock Analysis - Frequently Asked Questions

How have VVOS shares performed this year?

Vivos Therapeutics' stock was trading at $4.29 on January 1st, 2025. Since then, VVOS stock has increased by 41.5% and is now trading at $6.07.

How were Vivos Therapeutics' earnings last quarter?

Vivos Therapeutics, Inc. (NASDAQ:VVOS) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.01. The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $3.63 million. Vivos Therapeutics had a negative net margin of 76.82% and a negative trailing twelve-month return on equity of 170.43%.
Read the conference call transcript.

When did Vivos Therapeutics' stock split?

Vivos Therapeutics shares reverse split before market open on Friday, October 27th 2023.The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Vivos Therapeutics IPO?

Vivos Therapeutics (VVOS) raised $20 million in an IPO on Friday, December 11th 2020. The company issued 3,300,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners served as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

How do I buy shares of Vivos Therapeutics?

Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vivos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos Therapeutics investors own include Meta Platforms (META), NIO (NIO), Pfizer (PFE), Plug Power (PLUG), Advanced Micro Devices (AMD), Aridis Pharmaceuticals (ARDS) and Cocrystal Pharma (COCP).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/16/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:VVOS
• CIK: 1716166
• Web: www.vivoslife.com
• Phone: 866-908-4867
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vivos Therapeutics: $4.82
• High Price Target: $6.20
• Low Price Target: $2.25
• Potential Upside/Downside: -20.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.14 million
• Net Margins: -76.82%
• Pretax Margin: -76.82%
• Return on Equity: -170.43%
• Return on Assets: -77.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.77
• Quick Ratio: 0.77

Sales & Book Value

• Annual Sales: $15.03 million
• Price / Sales: 2.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.35 per share
• Price / Book: 4.50

Miscellaneous

• Outstanding Shares: 5,890,000
• Free Float: 5,713,000
• Market Cap: $35.75 million
• Optionable: Optionable
• Beta: 7.01